In July, we added 86 citations in DIDB, including 53 in vitro (with 17 articles published in July 2025) and 33 in vivo articles (with 32 articles published in July 2025).
3 NDA/BLAs approved in June 2025, including clesrovimab (ENFLONSIA), garadacimab (ANDEMBRY), and taletrectinib (IBTROZI) were also curated in DIDB.
You can check the citations that are recently published and entered in DIDB and all the NDAs/BLAs in DIDB.
As always, feel free to contact us if you have any questions or comments.